The purse-string suture has been widely used for bleeding control after percutaneous interventions through arteriovenous fistula (AVF) and graft (AVG), and it requires suture removal the next day. This study aimed to introduce a simple method using a tourniquet to facilitate hemostasis following AVF or AVG sheath removal after percutaneous procedures. Data were retrospectively collected and included all the consecutive patients who received bleeding control with a tourniquet after percutaneous AVF or AVG interventions. Hemostasis was facilitated using the tourniquet technique after sheath removal. A total of 1966 patients who received the tourniquet technique for bleeding control after percutaneous AVF or AVG interventions were included. Bleeding control was successfully achieved in all patients. Regarding complications, hematoma, thrombosis, and rebleeding occurred in 57 (2.9%), 11 (0.6%), and 8 (0.4%) patients, respectively. Neither pseudoaneurysm nor infection occurred in the patients. Age, gender, pre-existing diseases (including diabetes and hypertension), procedure count, sheath size, hemodialysis access type, and canalization route were similar between patients with and without complications. The primary patency rates at 6,12, 24, and 36 months were 85.0, 64.6, 53.8, and 41.6%, respectively. The tourniquet technique is an effective and safe approach for facilitating hemostasis after catheter-based percutaneous interventions of hemodialysis accesses.

中文翻译：

---

经皮血液透析瘘管和移植介入术后出血控制的简单止血带技术

荷包缝合线广泛用于动静脉瘘（AVF）和移植物（AVG）经皮介入术后止血，次日需拆线。本研究旨在介绍一种使用止血带的简单方法，以促进经皮手术后 AVF 或 AVG 鞘移除后的止血。数据是回顾性收集的，包括所有在经皮 AVF 或 AVG 干预后使用止血带控制出血的连续患者。去除鞘后使用止血带技术促进止血。共纳入 1966 名在经皮 AVF 或 AVG 干预后接受止血带技术控制出血的患者。所有患者均成功控制出血。关于并发症，血肿，血栓形成，和再出血分别发生在 57 (2.9%)、11 (0.6%) 和 8 (0.4%) 名患者中。患者均未发生假性动脉瘤和感染。有并发症和无并发症的患者的年龄、性别、既往疾病（包括糖尿病和高血压）、手术次数、鞘管大小、血液透析通路类型和导管通路相似。6、12、24 和 36 个月的主要通畅率分别为 85.0、64.6、53.8 和 41.6%。止血带技术是一种有效且安全的方法，可在基于导管的血液透析通路经皮干预后促进止血。有并发症和无并发症的患者的鞘管尺寸、血液透析通路类型和导管通路相似。6、12、24 和 36 个月的主要通畅率分别为 85.0、64.6、53.8 和 41.6%。止血带技术是一种有效且安全的方法，可在基于导管的血液透析通路经皮干预后促进止血。有并发症和无并发症的患者的鞘管尺寸、血液透析通路类型和导管通路相似。6、12、24 和 36 个月的主要通畅率分别为 85.0、64.6、53.8 和 41.6%。止血带技术是一种有效且安全的方法，可在基于导管的血液透析通路经皮干预后促进止血。